Eli Lilly and Company announced a significant expansion at its Pleasant Prairie facility Thursday. The pharmaceutical giant plans a $3 billion investment, which is expected to create 750 new jobs at ...
Prescription fills for weight loss drugs more than doubled in 2024 despite limited insurance coverage and high costs, ...
DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.
Ozempic and similar drugs have been linked to possibly helping diseases beyond diabetes and obesity. Are they miracle drugs?
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
Some people are taking tiny amounts of weight loss medications, hoping to drop pounds while avoiding side effects. Does it ...
The weight loss revolution is in full swing, with the number of patients receiving Wegovy (NVO) having doubled while those ...